康惠股份(603139) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥108,608,839.81, a decrease of 21.80% compared to the same period last year[4]. - The total profit for the period was -¥97,199,229.70, reflecting a decline of 167.23% year-on-year[4]. - The net profit attributable to shareholders was -¥92,300,339.12, down 211.97% from the previous year[4]. - The basic and diluted earnings per share were both -¥0.93, a decrease of 220.69% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2025 was CNY 356,141,252.19, a decrease of 11.93% compared to CNY 404,545,531.96 in the same period of 2024[21]. - Net profit for the first three quarters of 2025 was a loss of CNY 156,889,017.44, compared to a loss of CNY 47,782,213.85 in the same period of 2024, reflecting a significant increase in losses[22]. - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY -1.33, compared to CNY -0.38 in the same period of 2024, reflecting worsening financial performance[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,886,387,585.81, a slight decrease of 0.08% from the end of the previous year[5]. - The equity attributable to shareholders decreased by 15.45% to ¥724,839,306.46 compared to the end of the previous year[5]. - The company's total liabilities increased to CNY 1,140,973,925.89 in Q3 2025 from CNY 980,937,492.97 in Q3 2024, showing a rise in financial obligations[20]. - The total equity attributable to shareholders decreased to CNY 724,839,306.46 in Q3 2025 from CNY 857,322,192.02 in Q3 2024, indicating a decline in shareholder value[20]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥9,238,029.67, with a significant increase of 73.63% in cash outflows due to procurement and tax payments[5]. - Cash flow from operating activities for the first three quarters of 2025 was CNY 395,034,596.39, down from CNY 460,121,083.94 in 2024, indicating a decline in cash generation[25]. - The net cash flow from operating activities was -9,238,029.67, an improvement from -35,037,983.52 in the previous year[26]. - Total cash inflow from investing activities was 6,306,068.86, down from 50,350,737.66 year-over-year[26]. - The net cash flow from investing activities was -25,393,032.62, compared to -62,964,882.22 in the previous year[26]. - Cash inflow from financing activities totaled 287,442,770.40, a decrease from 351,117,999.19 year-over-year[27]. - The net cash flow from financing activities was 15,525,817.71, down from 61,594,907.49 in the previous year[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,458[10]. - The largest shareholder, Jiaxing Yuehe Zhichuang Technology Partnership, held 22.00% of the shares[10]. Operational Changes - The company’s subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., has begun operations, although it has not yet significantly impacted overall performance[13]. - The company has completed the cancellation of its wholly-owned subsidiary, Xi'an Xinliangfang Pharmacy Co., Ltd., on August 4, 2025, which did not have a major impact on financial performance[13][14]. - The company’s governance structure has been adjusted, with the controlling shareholder changing from Kanghui Holdings to Yuehe Zhichuang, and the actual controllers are now Li Hongming and Wang Xuefang[12]. Cost Management - Total operating costs for the first three quarters of 2025 were CNY 449,560,000.04, slightly down from CNY 455,454,003.35 in 2024, indicating a cost reduction strategy[21]. - The company reported a significant increase in credit impairment losses, amounting to CNY -62,123,737.00 in 2025 compared to CNY -3,896,391.46 in 2024[22]. - Research and development expenses increased to CNY 5,114,091.34 in 2025 from CNY 4,697,380.27 in 2024, indicating a focus on innovation despite financial losses[21]. - The company reported an investment loss of CNY -3,970,242.88 in 2025, contrasting with a gain of CNY 2,304,092.47 in 2024, highlighting challenges in investment performance[21]. Cash and Equivalents - The company's cash and cash equivalents decreased to RMB 78,494,908.73 from RMB 97,600,121.36, representing a decline of about 19.6%[17]. - The ending balance of cash and cash equivalents was 78,494,022.59, compared to 113,435,205.75 at the end of the previous year[27].